Continuing Application. In the event of a Transfer by a Stockholder of less than all of the Shares pursuant to Article II, the provisions of Section 4.01 shall continue to apply during the term of this Agreement to all Shares Beneficially Owned by the Stockholder.
Continuing Application. The terms of this Agreement will continue to apply throughout the Executive’s employment, regardless of:
a) the Executive’s length of service; or
b) any changes that may occur to the Executive’s position, duties and responsibilities, compensation or benefits, or other terms of employment; or
c) any changes to the Company as a result of a reorganization, plan of arrangement, reverse take-over, merger or acquisition.
Continuing Application. The provisions of this Clause Thirty-One shall remain in full force and effect and shall survive the termination or rescission of this Agreement, for any reason whatsoever.
Continuing Application. The provisions of this contract shall remain in full force and effect in so far as they remain to be performed and observed after completion of the sale and purchase of the Property.
Continuing Application. If the Consideration Shares subject to an Offer not accepted by the Purchaser or any assignee are not sold to a Third Party under section 2.8(c)(i) within the period of ninety (90) days referred to therein or sold in the open market under section 2.8(c)(ii) within the period of one (1) year from the date of the Offer, the provisions of this section 2.8 shall again apply.
Continuing Application. No later than thirty (30) days following the EFFECTIVE DATE, ENTREMED shall file, in the United States and any other country or region possible, a continuing patent application claiming priority to the United States Patent Application 08/102,767 (filed August 6, 1993) claiming the use of derivatives of 2-methoxyestradiol as anti-angiogenesis agents for conditions including ocular neovascularization, wherein the molecule is substituted at the 2 position of the estradiol ring with a) alkoxy groups and b) alkyl esters. ENTREMED shall file a petition to make special pursuant to 37 CFR 1.102 (d) with the United States Patent and Trademark Office in reference to such continuing application, and shall take all reasonable action to accelerate the prosecution of such application(s). ENTREMED shall also submit an Information Disclosure Statement at the time of United States filing of such continuing application which shall inform the Patent Examiner of the existence of U.S. Patent No 6,011,023 (Xxxxx et al.) and U.S. Patent No. 5,643,900 (Fotsis et al.) and all other references which are required to be disclosed pursuant to 37 CFR Section 1.56. ALLERGAN shall pay ENTREMED * Dollars ($*) upon issue of a U.S. patent containing claims substantially as described in this Section 8.2.
Continuing Application. The provisions of this Clause Twenty-Nine will remain effective and must survive the termination of this Contract.
Continuing Application. 1.3.1 In submitting a response to this PQQ it will be implied that you accept all the provisions of this PQQ including these terms and conditions and the CCS PQQ conditions as supplemented.
1.3.2 Paragraph 2 of this PQQ shall be deemed to be repeated at each and every stage of the Process up to and including close of clarifications with any se- lected Candidate and shall, for the avoidance of doubt, apply to all further in- formation and documentation provided or made available as part of this Proc- ess.
1.3.3 The Authority will require the successful contractor at the very end of this Pro- cess, prior to entering into the proposed Framework Agreement for the Re- quired Services, to supply evidence to support its PQQ Response, so it is ad- visable that Candidates ensure that such evidence can be made available up- on request should they be successful in this Process. The Authority reserves the right to deselect a Candidate prior to any award of contract, in the event that evidence to support the Candidate’s PQQ Response is not provided upon request at the relevant time. Candidates may further be asked, at any time in this Process, to clarify parts of their PQQ Response or to provide more detail.
1.3.4 If, at any time during the PQQ Process, there are any changes to the informa- tion provided by Candidates (including but not limited to information concern- ing contracting structures or the members and the structure of any consor- tium) the Candidate must advise the Authority as soon as practicable, even if its PQQ Response has been submitted prior to the required date of PQQ Re- sponse.
1.3.5 The Authority reserves the right to consider the effect of any changes and may request that a Candidate re-submit their Response so that it may assess the Candidate’s changed response to the PQQ. The Authority reserves the right to impose conditions on, or disqualify any Candidate who makes or suffers changes to any aspect of their PQQ Responses, unless substantial justifica- tion can be provided to the satisfaction of the Authority.
1.3.6 By responding to this PQQ, all Candidates shall be deemed to have con- sented to future changes in any other Candidate’s contracting structure, con- sortium structure or membership. The Authority will assess the effect that any changes may have on those Candidates continuing to be included in the pro- curement process and will take the steps necessary to ensure the Authority meets its legal and procurement obligations.
Continuing Application. 12 11.4 Acknowledgment...........................................13
Continuing Application. The Warrantholders Agreement is hereby amended by deleting the second parenthetical clause of the second recital thereof in its entirety and replacing it with the following:
